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Making gender bias visible allows to fill the gaps in knowledge and understand health records and 
risks of women and men. The coronavirus disease 2019 (COVID-19) pandemic has shown a clear 
gender difference in health outcomes. The more severe symptoms and higher mortality in men as 
compared to women are likely due to sex and age differences in immune responses. Age-associated 
decline in sex steroid hormone levels may mediate proinflammatory reactions in older adults, 
thereby increasing their risk of adverse outcomes, whereas sex hormones and/or sex hormone 
receptor modulators may attenuate the inflammatory response and provide benefit to COVID-19 
patients. While multiple pharmacological options including anticoagulants, glucocorticoids, 
antivirals, anti-inflammatory agents and traditional Chinese medicine preparations have been tested 
to treat COVID-19 patients with varied levels of evidence in terms of efficacy and safety, 
information on sex-targeted treatment strategies is currently limited. Women may have more benefit 
from COVID-19 vaccines than men, despite the occurrence of more frequent adverse effects, and 
long-term safety data with newly developed vectors are eagerly awaited. The prevalent inclusion of 
men in randomised clinical trials (RCTs) with subsequent extrapolation of results to women needs 
to be addressed, as reinforcing sex-neutral claims into COVID-19 research may insidiously lead to 
increased inequities in health care. The huge worldwide effort with over 3,000 ongoing RCTs of 
pharmacological agents should focus on improving knowledge on sex, gender and age as pillars of 
individual variation in drug responses and enforce appropriateness.  
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The influence of sex and gender on human health and diseases continues nowadays to be 
underestimated and underinvestigated in medical intervention. In particular, the lack of accurate sex 
and gender consideration to evaluate disparities in drug safety and efficacy hurts both women and 
men. This is particularly evident in clinical trials, where sex and gender inequality in subjects’ 
enrolment remains a substantial challenge.  
The current global health emergency, COVID-19, whose etiological agent has been identified to be 
SARS-CoV-2, has changed the world in an unprecedented way. While the society is facing this 
extraordinary catastrophe, scientist and clinicians need to recognize the phenotypical differences 
between men, women, and people with non-binary identities as a fundamental key to deeply 
understand the effects of this health crisis on different individuals, as well as to identify unbiased 
clinical protocols.  
Global Health 50/50, an independent, evidence-driven initiative to advance action and 
accountability for gender equality in global health, provided an overview of open-access sex-
disaggregated data from official national sources through the COVID-19 Data Tracker. This is the 
world’s largest database of sex-disaggregated data on COVID-19 health outcomes. The tracker 
currently collects sex-disaggregated data on vaccinations, testing, confirmed cases, hospitalizations, 
intensive care unit (ICU) admissions and deaths. Data are constantly collected from ministry of 
health websites, national statistics sites, death registers and government social media accounts. As 
the disease has spread worldwide, the May 2021 Update Report tracked the availability of data for 
198 countries - which together accounted for 99.9% of COVID-19 confirmed cases and reported 
deaths globally. As of May 2021, 51% (101) of the 198 countries being tracked reported sex-
disaggregated case data and 37% (73) reported sex-disaggregated death data, which was consistent 
with the proportion reporting in April. Across all available global data, slightly more women than 











account for similar numbers of confirmed cases, but the gender gap grows further along the 
pathway, with men accounting for a higher proportion of hospitalizations (53%), ICU admissions 
(64%) and deaths (57%). [1] 
Furthermore, sex-disaggregated COVID-19 data did not account for gender identity. Therefore, data 
on the impact of COVID-19 on transgender and non-binary people are lacking, although some 
efforts are in place to address this issue. 
Despite clear gender differences in COVID-19 health outcomes, no information on gender-targeted 
treatment strategies is currently available. Without this evidence, gender-specific health care needs 
can neither be identified nor adequately addressed, and treatment appropriateness is not warranted. 
Thus, in current and future clinical trials for COVID-19, variables of paramount importance such as 
sex and gender should be taken into serious consideration, not only in relation to disease features, 
but to tailor the appropriate therapies in order to eliminate gender blindness in medical research. 
Thus, as prophylactic and therapeutic treatment studies begin, sex and gender analyses should be 
included in the protocols.  
At the time of writing, the analysis of the clinicaltrials.gov database reported 3,517 items when 
searched for “COVID-19 and therapy”. The analysis also included synonyms, as “treatment (3,181 
studies), therapeutic (460 studies), therapeutics (158 studies), disease management (5 studies), 
COVID (3,449 studies), SARS-CoV-2 (1,132 studies), Coronavirus disease 2019 (191 studies), 
severe acute respiratory syndrome coronavirus 2 (128 studies), Novel Coronavirus (101 studies), 
2019-nCoV (35 studies), Coronavirus Disease 19 (22 studies), SARS Coronavirus 2 (14 studies), 
Wuhan coronavirus (1 study)”. 
Despite the huge amount of clinical protocols, and although both male and female individuals were 
considered eligible for the studies, no specific gender-analysis were foreseen in terms of differences 











treatments currently tested for COVID-19. The study focused on literature reports and ongoing 
clinical trials in the time frame March 2020-June 2021.  
 
2. Sex hormones and COVID-19 
2.1 Estrogen and progesterone  
Estrogens, in particular the main female sex hormone 17β-estradiol (E2), have been suggested to 
play a protective role in COVID-19. This seems to occur through different pathways including 
suppression of inflammatory storm, induction of anti-viral immune responses and enhancement of 
virus degradation within endolysosomes, resulting in endosomes and lysosomes fusion [2]. E2 
affects the activity or expression of different components of the renin–angiotensin-aldosterone 
system by upregulating the expression of ACE2, which appears to be higher in females than in 
males [3]. Binding of the SARS-CoV-2 spike protein to ACE2 induces its down-regulation, leading 
to reduced angiotensin (1-7) production in the lung and igniting acute respiratory failure [4,5]. 
Hence, E2-mediated ACE2 over-expression in female patients could contribute to the better 
outcome and lower death rate observed in female COVID-19 patients in comparison to males [6].  
The active role of estrogens in accelerating resolution of inflammation suggests that estrogens 
and/or selective estrogen receptor modulators (SERMs) attenuates the inflammatory response and 
its exacerbation [7–9]. The Annexin A1/formyl-peptide receptor 2 (AnxA1/FPR2) axis is one of the 
pathways involved in this interplay, which is also shared by glucocorticoids (GC), and could 
represent a mechanistic/pharmacological base for the potential protective action by estrogens in 
COVID-19 outcomes (Figure 1). Besides estrogens, progesterone (PG) also confers protection from 
severe lung injury by dampening the exaggerated inflammatory immune cascade, or “cytokine 











inflammation, reduce protein leakage into airways, and promote faster recovery by enhancing repair 
of pulmonary epithelial cells [10]. 
In accordance with the protective role of female sex hormones, data from the Italian Surveillance 
System [11] highlight how the lethality rate for COVID-19 is reduced in women of reproductive 
age (20–39 years of age) and sensibly lower than in men. Afterwards, it steadily increases from 
0.2% within the age range 40–49 to over 20% at 80–89, but an imbalance between women and men 
still remains. Supporting these hypotheses, a positive association between COVID-19 and 
menopausal status and a negative association with combined oral contraceptive pills use have been 
observed in large-scale self-reported data analysis in UK [12]. Moreover, a retrospective study of 
hormone therapy in female COVID-19 patients showed that the fatality risk for women >50 years 
receiving E2 therapy was reduced by over 50%. For younger, pre-menopausal women (15–49 
years), the risk of COVID-19 fatality is the same irrespectively of E2 treatment, probably because 
of higher endogenous E2 levels [13]. Intriguingly, when women with COVID-19 were stratified by 
menstrual status, pre-menopausal women had lower rates and short duration of hospitalization 
together with less requirement for respiratory support compared to post-menopausal women (see 
relevant Summary Box) [14]. 
2.1.1 Clinical trials on estrogen and progesterone in COVID-19 patients  
Based on the aforementioned evidence, gender-based clinical trials studying effects of estrogen 
therapy to attenuate severe complications of COVID-19 are required and could represent a 
successful approach (Figure 1). Administration of exogenous hormones could therefore represent a 
therapeutic/prophylactic approach or a treatment adjunct to reduce COVID-19 disease severity. 
Several clinical trials testing the effect of E2 and PG on clinical response and mortality of COVID-











In Mexico, a recruiting trial will investigate the effect of a combined E2 and PG patch 
(NCT04539626) in male ≥ 18 years and female ≥ 55 years’ patients with non-severe COVID-19. 
The study will evaluate the progression of clinical signs and symptoms (fever, dyspnea, cough, 
fatigue daily score) and any adverse outcome in comparison to placebo for 30 days. 
In the USA, a phase 2 clinical trial (recruiting) is investigating whether symptom severity can be 
reduced with E2 administered by transdermal patch (NCT04359329), in adult men ≥ 18 years and 
older women with COVID-19 ≥ 55 years. A further USA phase 2 trial (active, not recruiting) is 
assessing whether E4 is safe and effective at protecting participants from the more severe symptoms 
of COVID-19 (NCT04801836). The study will monitor the progression to more severe disease in 
men and post-menopausal women hospitalized with COVID-19 not yet needing breathing help. 
In Qatar, a phase 2 clinical trial (not yet recruiting) will investigate whether a transdermal E2 gel 
will protect adult men and postmenopausal women with confirmed COVID-19 against progression 
to more severe disease (NCT04853069). 
In the USA, a pilot trial testing whether symptoms severity can be reduced with oral PG in men 
(NCT04365127) has been completed and showed very encouraging data. Indeed, results suggested 
that administration of PG at a dose of 100 mg twice daily by subcutaneous injection represents a 
safe and effective approach to treat COVID-19 by improving clinical status among men with 
moderate to severe illness [15]. 
Another phase 2 (not yet recruiting) clinical trial in the USA (NCT04865029) will analyze whether 
a short systemic steroid therapy with E2 and PG, administered early to hospitalized and confirmed 
COVID-19 positive patients of both sexes in addition to standard of care, can reduce the severity of 
symptoms and improve outcomes.  
Other clinical trials are ongoing regarding the efficacy of SERMs. Tamoxifen is a nonsteroidal 











breast tissue while acting as an agonist or a partial agonist in the uterus, bone and heart. Therefore, 
tamoxifen is an effective treatment for ER+ breast cancer and postmenopausal osteoporosis, but it 
increases risk of endometrial cancer and cardiovascular disease [16]. Tamoxifen has shown 
potential for drug repurposing in COVID-19 [17]. This agent decreases the rate of vesicular 
transport though the recycling and secretory pathways and inhibits phagocytosis [18]. 
In Egypt, two distinct clinical trials (not yet recruiting) will analyze the effects of a combined 
therapy with isotretinoin (down-regulator of ACE2) and tamoxifen in the protection against SARS-
CoV2 in adult female and male patients (Phase 2, NCT04389580) and of the combination of all-
trans retinoic acid (for its anti-inflammatory, anti-platelet and fibrinolytic activities) with tamoxifen 
as potential treatment for the lung complication of COVID-19 (Phase 2, NCT04568096). Estrogens 
and tamoxifen are not the only drugs showing a potential utility in COVID-19 management. 
Raloxifene, a benzothiophene-derived SERM [16], has been recently demonstrated to be effective 
in treating viral infections for its action on ER, suggesting its potential for drug repurposing [19]. 
Raloxifene acts as an agonist in the bone, cardiovascular system and liver, but shows antagonistic 
effects in human breast and uterus. Of note, a specific mechanism of inhibition of Ebola virus 
infection by raloxifene has been suggested [20]. This agent interferes with viral replication within 
host cells by reducing the expression of sphingosine and the related accumulation of calcium ions 
within endolysosomes preventing viral escape. Raloxifene decreases the influenza A virus titer in 
nasal epithelial cells isolated from female but not male patients [21], and inhibits RNA replication 
of HCV [22]. Of note, raloxifene has also been demonstrated to antagonize interleukin (IL)-6 
signaling in severe COVID-19 patients protecting against acute respiratory distress syndrome [23]. 
These findings strongly recommend raloxifene as a potential therapeutic strategy for COVID-19, 











2.2 Androgens and anti-androgens  
The higher death rate observed in men compared with women put androgens (i.e. testosterone, T) 
under the spotlight as possible players in the exacerbation of COVID-19 symptoms. Plasma T levels 
decrease in elderly men and in the presence of highly prevalent comorbidities in COVID-19 such as 
obesity and diabetes [24]. Recent data report that the gradual decline in total and free testosterone 
levels correlates with serious pulmonary complications requiring advanced care [25]. T has been 
linked to thromboembolic events following its exogenous administration to treat a number of 
diseases, including hypogonadism  [26–28]. The majority of cases described are not linked to 
hypogonadism, where T therapy displays beneficial actions well beyond adverse effects [29,30]. 
Unregulated testosterone activity or excessive levels may conceivably trigger detrimental pathways, 
leading to an unbalanced coagulative physiology, thus facilitating thrombi formation as observed in 
men affected by COVID-19. A number of reports suggest monitoring homocysteine levels before 
and during therapy, as thromboembolic events have been consistently described after 6-12 months 
of treatment, despite anticoagulation therapy [26,31]. Homocysteine is a widely accepted risk factor 
for cardiovascular disease, and has been linked to hyperactive platelet aggregation mediated by H2S 
(Figure 1) [32]. Testosterone has also been associated with the generation of H2S, whose plasma 
levels are higher in males than in females [33]. Therefore, T (and male gender) per se might be a 
risk factor for vascular thrombosis (see relevant Summary Box). 
Studies in animal models and humans documented that hypogonadism is associated with increased 
pro-inflammatory cytokines, while increased testosterone levels following exogenous treatment 
suppress the release of IL-1β, IL-6, IL-1, tumor necrosis factor (TNF)-α and leukotrienes 
[29,30,34]. In elderly men, the decline of testosterone correlated with the onset of a 
proinflammatory condition [35]. The increased death rate in aged male patients with COVID-19 
suggests that testosterone plays a protective role in the progression of COVID-19 infection due to 











bacterial model of prostate inflammation, generating an inefficient inflammatory response 
associated with a neutrophil N2-like phenotype [37]. Neutrophils play a key role in innate immunity 
and in inflammation as they also drive the resolution pathway by triggering mechanisms based on 
different cell mediators/receptors [38]. 
 2.2.1 Clinical trials on androgens or anti-androgens  
As for estrogens, several clinical trials testing the effect of T on the clinical response and mortality 
of COVID-19 patients are underway at the time of preparation of this review and are discussed 
below. 
Interestingly, T increases ACE-2 expression, whereas dihydrotestosterone (DHT) significantly 
induces the expression of transmembrane protease serine 2 (TMPRSS2), thereby increasing viral 
entry [39]. A randomized interventional comparative phase 4 clinical trial in Egypt (NCT04623385, 
not yet recruiting) in adult male and female patients will test the effect of 13-cisretinoic acid 
(isotretinoin, a potent inhibitor of DHT) plus testosterone, which could up-regulate pulmonary 
protective pathways and at the same time protect against thrombosis. Other Egyptian trials in both 
female and male adult patients will test isotretinoin alone (NCT04577378, Phase 2, not yet 
recruiting) or in combination with the ACE inhibitor captopril (NCT04578236, Phase 2, not yet 
recruiting). 
Trials exploring anti-androgen therapies aiming to reduce disease severity by inhibiting TMPRSS2 
are also underway in different countries including Sweden (enzalutamide, in both sex adult patients, 
Phase 2, recruiting, NCT04475601 [40]), USA (bicalutamide in male patients, NCT04509999, 
Phase 3, recruiting, and camostat+bicalutamide in all sex elderly patients, NCT04652765, phase 1 
recruiting) and Brazil (proxalutamide in male patients, NCT04446429, completed and now 
extended to female patients, phase 3, NCT04853134 active not recruiting; proxalutamide in 











proxalutamide in male and female patients in Intensive Care Unit, recruiting phase 3 












Figure 1. Androgens and estrogens actions, effects and mechanisms: a possible role in contrasting severe COVID-19 
outcomes. (T, Testosterone; E2, estradiol; PG, progesterone; GC, glucocorticoid; H2S, hydrogen sulphide; LXA4, 














Summary of highlights, strength and limitations of sex hormones in COVID-19 patients. 
 
3. Coagulative disorders therapy and COVID-19 
A systematic review estimated that 17.3% of critically ill patients with COVID-19 had venous 
thromboembolism (VTE) [41]. SARS-CoV2 induces a thrombo-inflammatory phenotype, 
characterized by endotheliopathy, hypercoagulability and coagulation activation resulting in 
increased risk of thromboembolic events [42]. Endothelial dysfunction as measured by markers of 
endothelial cell and platelet activation such as von Willebrand factor and soluble P-selectin is a key 
feature of COVID-19-associated coagulation disorder, and may be associated with critical illness 
and death. In a cross-sectional study of 68 adult patients hospitalized with a confirmed diagnosis of 
COVID-19, among all patient characteristics analyzed, only sex showed a significant difference in 
distribution between intensive care unit (ICU) and non-ICU subgroups, with fewer females 
requiring ICU admission [43]. Regrettably, no sex stratification was performed for treatment 












3.1 Clinical trials on anticoagulants 
A meta-analysis from direct oral anticoagulant (DOAC) trials found a sexual dimorphism in 
outcomes, with male patients being more protected from stroke/systemic embolic events and female 
patients more protected from major bleeding events [44]. It has been suggested that underestimation 
of kidney function via standard equations in women possibly leads to suboptimal dosing and low 
efficacy of DOACs, which are excreted by the kidneys to a variable extent [45,46]. 
While evidence largely comes from real-world studies, large international prospective clinical trials 
are ongoing to confirm benefit of antithrombotic therapy in COVID-19 patients. Regrettably, focus 
on sex differences is limited despite clearly distinct clinical presentation and response to treatment 
in males vs. females [47]. For instance, landmark clinical trials in the ‘90s showed remarkable 
sexual dimorphism in the response to low-dose aspirin in primary prevention [48,49]. 
A retrospective observational study carried out in 24 centers in France reported a beneficial effect 
of oral anticoagulant prior to hospitalization for COVID-19 on disease outcomes. Out of nearly 
3,000 study subjects, about 60% patients were males. Among other factors, male sex was 
significantly associated with ICU admission and in-hospital mortality. Of note, in patients not on 
anticoagulants prior to hospitalization, parenteral heparin or LMWH treatment started during 
hospitalization was not associated with a better prognosis (Figure 1). A smaller retrospective, 
single‐ institution study from the U.S. including patients who received therapeutic anticoagulation 
for at least 1 month before COVID diagnosis yielded consistent findings. While the majority of 
patients were females with a median age of 78, 69% of patients who died were male [50].  
In contrast, a register‐ based cohort study in Sweden including over 400,000 subjects with a 
recorded diagnosis of heart disease showed that ongoing DOAC use in patients with AF was not 
associated with lower risk of severe COVID-19 compared with patients with AF or those with 











group, DOAC users were older and, more often, female compared with AF patients with no DOAC 
use. Regrettably, study outcomes were not stratified by sex (see relative Summary Box). 
Recently, retrospective [52] and cohort studies [53] from Italian research groups reported that 
prophylactic doses of low-molecular-weight heparin (LMWH: enoxaparin 4000 IU, once daily) 
efficaciously reduced the mortality in hospitalized COVID-19 patients with mild/moderate disease. 
Conversely, a recent systematic review and meta-analysis of eight retrospective observational 
studies of nearly 3,000 patients did not highlight any significant variations in mortality rate in 
patients receiving prophylactic doses of heparin [54]; however, the analysis was reported regardless 
of age and sex. 
While outpatients with mild COVID-19 are encouraged to increase mobility, hospitalized patients 
with COVID-19 should undergo risk stratification for venous thromboembolic event prophylaxis 
[55]. Three international trials spanning four continents (NCT02735707; NCT04372589; 
NCT04505774) are assessing the benefit of full doses of anticoagulants to treat moderately ill or 
critically ill adults hospitalized for COVID-19, compared to a lower dose often used to prevent 
blood clots in hospitalized patients. Enrolment, however, was paused among critically ill COVID-
19 patients requiring ICU support, as therapeutic anticoagulation drugs did not reduce the need for 
organ support and potentially induced harm. In the multicenter, randomized INSPIRATION trial 
[56], intermediate-dose compared with standard-dose prophylactic anticoagulation did not improve 
the primary composite efficacy outcome or its major components, including all-cause mortality and 
VTE. Similarly, in an open-label, multicenter, randomized, controlled trial including 615 patients 
hospitalized with confirmed COVID-19 and elevated D-dimer concentration, a 30-day course of 
therapeutic anticoagulation with rivaroxaban 20 mg daily (and enoxaparin 1 mg/kg twice daily for 
clinically unstable patients) did not result in better clinical outcomes when compared with in-











days with rivaroxaban or enoxaparin led to a higher incidence of major or clinically relevant non-
major bleeding than did in-hospital prophylactic anticoagulation [57]. 
A prospective multihospital registry of nearly 5,000 adult hospitalized COVID-19 patients (53% 
males) with a mean follow-up of 3 months found that VTE, arterial thromboembolism and all-cause 
mortality occurred with a higher frequency (7.3%) during the post-discharge period than previously 
reported [58]. Age >75 years was among key predictors of post-discharge thromboembolic events 
and death. Post-discharge thromboprophylaxis consisting of prophylactic dose rivaroxaban, 
apixaban or enoxaparin was prescribed in 12.7% of the population. The use of post-discharge 
anticoagulants, mostly at prophylactic doses, was associated with a striking 46% reduction of major 
thromboembolic events and death risk.  
 
Summary of highlights, strength and limitations of coagulative disorders therapy in COVID-19 patients. 
 
4. The RAAS and COVID-19  
ACEIs and ARBs are recommended as first-line treatments for patients under 55 years with 











congestive cardiac failure. There are several controversial hypotheses on the potentially harmful or 
beneficial effects of antihypertensive drugs acting on the renin-angiotensin-aldosterone system 
(RAAS) in COVID-19 [59,60]. SARS-CoV-2 interfaces with the RAAS through ACE2. It is now 
understood that SARS-CoV-2 utilizes the ACE2 receptor as its main entry portal in the target cell 
and possibly as a route of secondary “metastatic” end-organ disease [61]. The interaction between 
the virus and ACE2 may be one determinant of its infectivity, and there are concerns that RAAS 
inhibitors may change ACE2 expression and hence COVID-19 virulence. In vitro and in vivo 
studies have demonstrated that ACEIs as well as ARBs can significantly increase ACE2 expression, 
thereby facilitating SARS-CoV-2 entry into cells [62,63]. Mechanistically, it is possible that ACE2 
tissue level changes in response to ACEIs/ARBs in humans, but large clinical studies have not yet 
confirmed this. However, it has also been described that viral binding to ACE2 decreases its surface 
expression and prevents angiotensin-II cleavage by ACE to generate angiotensin1–7, which 
counterbalances the effect of angiotensin-II signaling through AT1R. Hence, binding of angiotensin-
II to AT1R leads to increased pulmonary vascular permeability, resulting in lung injury [64,65]. By 
blocking AT1R-mediated angiotensin-II adverse effects and increasing ACE2-mediated production 
of angiotensin1–7 production, ARBs may counteract this effect and reduce lung damage [4].  
 
4.1 ACE inhibitors and angiotensin-II receptor blockers use in COVID-19 patients  
A literature search for ACE2 updated to June 2021 returned more than 30,000 articles, largely 
classified as reviews. A big push to publish data on ACE2 comes from the current pandemic event, 
marking a gender difference in disease evolution. Indeed, women seem to be more protected than 
men from disease progression, and this evidence has been linked to higher ACE2 levels in female 
subjects. However, ACE2 identification goes back to more than 20 years ago, and research 
continued for years in this field because ACE2 is strongly engaged in blood pressure regulation and 











inhibit the activity or expression of different components of the RAAS system. E2 upregulates 
ACE2 expression [3], which is accordingly higher in females than in males. Binding of SARS-
CoV-2 spike protein to ACE2 induces ACE2 down-regulation, which in turn leads to decreased 
angiotensin1-7 production in the lung, resulting in acute respiratory injury. Therefore, higher 
estrogen levels leading to ACE2 over-expression could account for better outcomes and improved 
survival in female patients [66]. The X-linked nature of the ACE2 gene, with females showing a 
wide range of phenotypes, may have a greater role than that defined so far in the gender differences 
observed in COVID-19 pathogenesis.  
Estrogens influence the vascular system by inducing vasodilatation, inhibiting vascular remodelling 
processes, and modulating both the RAAS and the sympathetic system. This leads to a protective 
effect on arterial stiffness during reproductive age that is dramatically reversed after menopause. 
Having established that it is essential not to suspend antihypertensive therapies even in case of 
coronavirus infection, it is important to underline this also in terms of sex differences. Men and 
women differ in prevalence, awareness, and control rate of hypertension in an age-dependent 
manner. Studies suggest that sex hormones changes play a pivotal role in the pathophysiology of 
hypertension in postmenopausal women. Data on the efficacy of antihypertensive therapy between 
genders are conflicting, and the underrepresentation of aged women in large clinical trials could 
influence the results. An interesting review by Ramirez and Sullivan, entitled Sex Differences in 
Hypertension: Where We Have Been and Where We Are Going [67], highlights that while men have 
long been known to display greater increases in blood pressure compared with women, only 
recently intense efforts have been made to enhance the awareness that women show similar risks to 
develop hypertension. Due to a) the uncertainty around harmful or beneficial effects of ACEIs and 
ARBs in COVID-19 patients, b) the need not to suspend antihypertensive therapies even in case of 
COVID-19 infection, and c) the evidence that antihypertensive therapy has been profiled mainly in 












4.2 Clinical trials of ACE inhibitors and angiotensin-II receptor blockers in COVID-19 patients  
Based on several observational studies, there is accumulating evidence that ACEIs and ARBs do 
not increase the risk of contracting SARS-CoV-2 infection. Specifically, there is no evidence of 
harm due to anti-RAAS medications in COVID-19 [68–70]. On the other hand, conflicting findings 
regarding the role of ACEIs and ARBs as prognosis modifiers in COVID-19 hospitalized patients 
have been reported [66,71–73]. Published studies on this research question generally suffer from 
small sample size, which prevents extensive analyses. Furthermore, the identification of all 
covariates related to prior use of chronic medications may not be accurately evaluated in the setting 
of a healthcare emergency, when data are collected prospectively. The mixed quality of studies 
investigating whether ACEIs and ARBs use can modify the prognosis of COVID-19 is due to the 
fact that two meta-analyses of observational studies reported contrasting results. One meta-analysis 
suggested a protective effect of RAAS inhibitors regarding all-cause mortality and critical illness 
[74], while the other one found no significant association with all-cause mortality [75]. In addition 
to contradictory results, these meta-analyses are problematic because they included an observational 
study that has since been retracted [76]. This highlights the need for large-scale studies using 
appropriate methods to investigate whether prior ACEIs and ARBs use among COVID-19 patients 
improves or worsens outcomes. Analysis of ongoing trials from clinical trials.gov reports 
encouragingly studies testing the effect of angiotensin modulators on clinical outcomes in COVID-
19 patients at high-risk for cardiovascular disease recruiting all sexes (NCT04591210, 












Summary of highlights, strength and limitations of RAAS in COVID-19 patients. 
 
5. Antiviral therapy 
Antiviral drugs (i.e. remdesivir, lopinavir/ritonavir, favipiravir, umifenovir) developed for viruses 
other than SARS-CoV-2 have been among the first drugs proposed for the treatment of COVID-19 
(Table 2). These drugs can inhibit either viral entry (via the ACE2 receptor and TMRSS2), viral 
membrane fusion and endocytosis, or the activity of the SARS-CoV-2 3-chymotrypsin-like protease 
and the RNA-dependent RNA polymerase [77]. Remdesivir is an antiviral drug of the nucleotide 
analogue class developed for the treatment of Ebola virus disease and also used for the treatment of 
SARS-CoV-2 infections [78]. The association of two antiviral drugs such as lopinavir and ritonavir, 
used for the treatment of HIV, were also proposed for SARS-CoV-2 infection in the first phase of 
the pandemic. Lopinavir is a protease inhibitor, while ritonavir enhances its pharmacological 
exposure by inhibiting the cytochrome P450 (CYP) isoenzyme 3A4. [79] In a recent published 
meta-analysis, remdesivir did not demonstrate efficacy for hospitalized COVID-19 patients [80]. 











for treatment of hospitalized patients with pneumonia under oxygen therapy not requiring high-flow 
oxygen or mechanical ventilation or extracorporeal oxygenation and with onset of symptoms for 
less than 10 days. Another systematic review and meta-analysis assessing the efficacy and safety of 
lopinavir/ritonavir in COVID-19 patients reported no significant advantage and more adverse 
events in the use of these drugs over standard of care (supplemental oxygen, ventilation, antibiotic 
agents, vasopressor support, renal replacement therapy, and extracorporeal membrane oxygenation), 
or over other antiviral agents [83]. Thus, the lopinavir/ritonavir association is not used for the 
treatment of COVID-19 in clinical practice and its off-label use has been suspended by EMA.  
Two broad-spectrum antiviral agents, favipiravir and umifenovir, are being tested for the treatment 
of SARS-CoV-2 infection. Umifenovir is approved in Russia and China for prophylaxis and 
treatment of influenza, and it exerts its antiviral effects via a direct-acting viricidal activity and by 
inhibiting several stages of the viral life cycle [84]. Favipiravir is used to manage influenza and has 
the potential to treat RNA virus infections by inhibiting RNA polymerase activity [85]. Both 
favipiravir and umifenovir are now under investigation in many clinical trials but are not approved 
in Europe and USA due to limited clinical evidence. Preliminary results suggest a potential activity 
of favipiravir in the treatment of the patients in mild-to-moderate COVID-19, in particular with 
regard to the time of clinical cure [86].  
As for viruses other than SARS-CoV-2 -19, published evidence shows that the efficacy and safety 
of antiviral drugs differs between sexes [87] and the adverse reactions to antiviral drugs are 
typically more serious in females than males. The beneficial effects of antiviral treatments for viral 
disease might differ by gender likely due to two main reasons: the first one involves the 
pharmacokinetics profile of men and women, and the second one refers to sex hormone status that 
could influence the outcomes of the antiviral therapy [87]. Treatment of the infection caused by 
Herpes simplex or influenza A viruses seems to induce better clinical and virologic outcomes in 











drugs reported higher use of antiviral drugs among men (see relevant Summary Box). The first 
study by Rivera et al. performed in the United States on 2186 adults with invasive cancer and 
confirmed diagnosis of COVID-19 analyzed a subcohort of patients receiving remdesivir [88]. The 
study shows that the probability to receive remdesivir tended to be higher in males (1.24 - CI: 0.84–
1.85). The second study by Vernaz et al. was conducted in Switzerland and analyzed a cohort of 
patients receiving lopinavir/ritonavir (83 patients) versus standard of care [89]. The authors reported 
that the probability of receiving lopinavir/ritonavir was also higher in men (p=0.05). As discussed 
by Rivera et al., a possible explanation of this higher use among men might be that male patients, 
who are more vulnerable to COVID-19 such as obese patients and patients with hypertension, are 
more likely to receive any anti–COVID-19 therapy. A randomized, double-blinded, placebo-
controlled, clinical trial by Beigel et al. analyzed 541 patients (352 males; 189 females) in treatment 
with remdesivir and 521 in treatment with placebo (332 male, 189 female) [90]. While reporting a 
benefit in the use of remdesivir for both sexes, the authors showed no difference between male and 
female in the recovery rate ratio (males: 1.30 (1.09–1.56); females: 1.31 (1.03–1.66)). Anyway, no 
specific outcome for mortality and safety was shown in relation to sex. As for safety, a recent meta-
analysis reported that remdesivir could be safely administered to hospitalized patients [91]. A 
pharmacovigilance study published in preprint by Zhang and colleagues analyzing data from the 
FAERS reported a network association of remdesivir with cardiac arrest in both males and females. 
The authors also reported that, while women are at increased risk for hypoxia, hypotension and 
renal impairment, remdesivir treatment in male patients is associated with respiratory failure [92].  
5.1 Clinical trials on antiviral drugs and COVID-19 in relation to gender  
Two studies in clinicaltrials.gov, assessing the use of antiviral agents for COVID-19, reported in the 
summary schedule a stratification of results by sex: NCT0468443 (completed) and NCT04569851 
(enrolling). Unfortunately, none of the studies has reported outcomes yet. Moreover, although 











the results by specific treatment and gender/age was shown in the summary schedule, nor was found 
information about a possible stratification of pre- and post-menopausal women (see relevant 
Summary Box).  
 
Summary of highlights, strength and limitations of antiviral therapy in COVID-19 patients. 
 
6. Monoclonal neutralizing anti-SARS-CoV-2 antibodies 
Monoclonal antibodies (mAbs) represent a novel therapeutic approach for the treatment of non-
hospitalized COVID-19 patients. These drugs have been approved by FDA and EMA, and have 
been recently added to the therapeutic offer for recently diagnosed (3 days) COVID-19 patients 
above age 12 who do not require supplemental oxygen and are at high risk of progressing to severe 
COVID-19. The neutralizing mAbs against SARS-CoV2 are bamlanivimab, bamlanivimab 
associated with etesevimab, and the combination casirivimab and imdevimab.  
With regard to bamlanivimab and etesevimab, these drugs are potent antispike neutralizing mAbs 
originating from two different patients recovered from COVID-19 in North America and China, 
respectively. The rationale of combining these two compounds comes from preclinical data 
indicating that etesevimab can interact with a different epitope with respect to bamlanivimab. Thus, 











bamlanivimab. These drugs have been approved in confirmed COVID-19 patients according to the 
BLAZE-1 study. This study is a still recruiting randomized phase 2/3 multicentric trial composed 
by 9 arms. Indications that such combination may represent an effective treatment emerged also 
from the reduced number of hospitalizations, emergency room access or death within 28 days after 
treatment. Similar results were found in the at-risk population also including pregnant and pediatric 
populations (12-17 years) with one or more predisposing factors for severe disease progression. 
Another mAb combination is REGN-COV2, i.e. the association of casirivimab and imdevimab. 
Such combination is made of two recombinant human IgG1 against SARS-CoV-2 mAbs 
unmodified in their Fc regions. Casirivimab and imdevimab bind to non-overlapping epitopes of the 
spike protein RBD. This combination has been provisionally approved in adult and pediatric (above 
12 years of age) outpatients. However, the efficacy, safety and tolerability of REGN-COV2 is still 
under evaluation in a randomized, quadruple-blind, placebo-controlled clinical trial (still recruiting, 
NCT04425629).  
Anti-COVID-19 mAbs can be routinely used in the clinical context; however, these drugs could be 
randomly assigned considering that these EMA/FDA approved drugs can be prescribed and 
requested with a therapeutic interchange approach. An observational study has just been registered 
with the aim of evaluating in a pragmatic way the therapeutic exchange policy for these drugs and 
will include adult and old patients, both males and females. There will be three treatment arms 
(bamlanivimab, casirivimab + imdevimab, and bamlanivimab + etesevimab). This study will help 
compare the effectiveness of different mAbs that has not been directly tested yet. 
Regdanvimab, another mAb directed against the Spike protein, is provisionally approved by EMA 
for reducing risk of hospitalization in mild COVID-19 patients at high risk of progressing to severe 
form of the disease. Regdanvimab is currently evaluated in a phase 2/3 (still recruiting) randomized, 
parallel-group, placebo-controlled, double-blind clinical trial conducted in both sexes in SARS-











Biochemical modification in the Fc portion of the Ab, along with other modifications such as 
PEGylation, are additional approaches to improve properties of this type of treatment for severe 
patients. AZD7442 is a combination of two mAbs (AZD8895 and AZD1061) for intramuscular 
administration under phase III trial (still recruiting, NCT04723394) characterized by substitutions in 
aminoacid composition in their Fc fraction with the aim of extending their half-lives. The 
modification reduces Fc effector function and decreases the potential risk of antibody-dependent 
enhancement of disease. The presence of sub-concentrations of Ab or non-neutralizing Ab has been 
associated with enhancement of viral entry, replication in target cells and cytokine release [93]. 
After vaccination, complete immunization may take several weeks, thus passive immunization post-
prophylaxis, as the one proposed in the above study, might represent an immediate long-term 
protection since modifications of Fc regions would prolong their half-life for weeks or even months 
[94]. The intramuscular use of this mAb is under evaluation and might help to simplify their use.  
Studies are still ongoing and may offer the advantage to highlight gender difference in recruited 
subjects. Unfortunately, results and ad interim analyses are not available yet. We expect that the 
data deriving from the use of these drugs in mild COVID-19 patients stratified by sex or age could 
represent a great advance in the knowledge of their efficacy and safety in specific populations 
allowing specific tailoring of the therapeutic strategy. Therefore, based upon the above evidence, 
we expect that these sex-driven differences in mAb disposition may also occur in COVID-19 













Summary of highlights, strength and limitations of neutralizing antibodies therapy in COVID-19 patients. 
 
7. Immunosuppressive and immunomodulatory drugs 
Physiologic gender-related differences in immune responses contribute to the gender gap in 
COVID-19 outcomes, as females most likely experience a mild disease compared to males [95]. 
The immune system hyperactivation in response to SARS-CoV-2 infection justifies the use of 
immunomodulatory and immunosuppressive drugs routinely used for treatment of autoimmune 
diseases or after solid-organ or hematopoietic stem cell transplantation [96]. SARS-CoV-2 deeply 
alters the immune balance in males by causing hyperactivation of kinin, complement, and 
coagulation cascades and enhancing macrophage-mediated phagocytosis, massive pro-inflammatory 
cytokine release (cytokine storm), and amplification of inflammation and immune responses, 
ultimately leading to pulmonary edema, thrombotic microangiopathy and acute respiratory distress 
syndrome (ARDS) [97]. Sex hormones can deeply influence composition and functions of the 
immune system favoring T helper 1 (Th1) and B cell-mediated responses, also in SARS-CoV-2 











pro-inflammatory cytokines, such as IL-8 and IL-18, and of non-classical monocytes, while females 
have an enhanced T cell-mediated immune response and lower cytokine levels [100]. Therefore, 
based on gender differences in SARS-CoV-2 epidemiology and immune responses during 
infections, gender-related variations in responsiveness to immunomodulatory and 
immunosuppressive drugs repurposed for treatment of COVID-19 can be foreseen. 
7.1 Immunosuppressive therapies 
Few prospective studies with immunosuppressive or immunomodulatory drugs have been 
conducted for Covid-19 treatment, while most of available data come from observational studies of 
incidence and outcomes of solid organ or hematological transplanted patients under 
immunosuppressive treatment, or subjects with autoimmune disorders [101]. Two large nationwide 
studies on liver transplant patients under immunosuppressive therapies have been conducted in 
Europe; however, both studies started with the bias that more than 70% of recruited subjects were 
males. Incidence of COVID-19 in these subjects is reported to be low probably because of self-
isolation [102]. Calcineurin and mTOR inhibitors have a protective role in liver transplant patients 
as drug continuation is associated with a mild-moderate disease, while immunosuppression 
discontinuation right after COVID-19 diagnosis or mycophenolate therapy are related to worse 
outcomes [103]. Mycophenolate, a reversible non-competitive inhibitor of purine and DNA 
synthesis essential in lymphocytes, might synergistically deplete T lymphocytes during SARS-
CoV-2 infection, which impair viral clearance and contribute to poor prognosis [103,104]. In the 
SETH study, a similar number of liver transplant females develop either mild/moderate or severe 
disease (19% vs 13%; p = 0.189) [105]. However, gender-based statistical analysis was not 
performed, and some female-related pharmacokinetics differences in cyclosporine or tacrolimus 
concentrations might have been diluted within the large number of males (71.2%) enrolled in the 
study [106,107]. Based on the beneficial effects of cyclosporine, tacrolimus, and everolimus in 











II TACROVID clinical trial has been designed to evaluate the efficacy and safety of 
methylprednisolone pulses, tacrolimus, and standard of care in severe COVID-19 patients [108]. 
TACROVID is still recruiting (NCT04341038), and patients are randomly assigned 1:1 to the 
experimental arm receiving methylprednisolone pulses of 120 mg/day for three consecutive days 
and tacrolimus twice daily to achieve a trough concentration of 8-10 ng/mL.  
In a retrospective, single-center, observational study conducted on 607 Spanish patients, gender was 
not reported as a risk factor for death in a multivariate analysis, while cyclosporine at accumulated 
dose of 300 mg significantly decreased mortality of COVID-19 patients [109]. The investigators 
also considered gender-based differences in cyclosporine pharmacokinetics. This high efficiency of 
cyclosporine in reducing 4-fold the mortality among COVID-19 patients might be related to the 
ability to modulate immune responses avoiding hyperactivation of immune cells and tissue damage, 
and to inhibit viral replication likely by interfering with cyclophilin, which is important in the 
SARS-CoV-2 life cycle [110]. An Italian study confirms these data, supporting the gender-
independent protective role of calcineurin inhibitors from developing severe COVID-19, especially 
among transplanted patients [111].  
7.2 DMARDs 
Drugs for treatment of rheumatoid arthritis and other autoimmune diseases have shown similar 
efficacy in reducing hospitalization and death rates compared to the general population [112–115]. 
Compared to transplanted patients, subjects with autoimmune disorders enrolled in these studies 
were mostly females [116]. Results from a US study showed similar hospitalization rates between 
patients with or without rheumatic disease, and similar mortality; however, multivariate analysis 
was not adjusted for type of immunosuppressive therapy, and management of immunosuppressive 
medications during SARS-CoV-2 infection was not known in over 60% of study subjects, thus 











Patients with rheumatic diseases under immunosuppressive agents or DMARDs are not at increased 
risk of severe COVID-19 with incidence of positivity for SARS-CoV-2 infection ranging from 
0.22% to 1.25% in three Italian surveys [118–120]. In addition, older males with rheumatoid 
arthritis treated with methotrexate are more likely to require hospitalization for Covid-19 compared 
to females with other rheumatologic diseases [121]. Similarly, Gianfrancesco et al. confirmed 
increased hospitalization rate of males with rheumatic disorders and under steroid treatment (>10 
mg/day prednisone-equivalent glucocorticoids) [122].  
Overall, DMARDs have shown a protective role against severe COVID-19 in patients with 
autoimmune and rheumatologic disorders in both sexes, except for methotrexate that seems to be 
linked to a higher risk of hospitalization especially in older males. 
 
7.3 JAKi 
JAKi, such as ruxolitinib and baricitinib, have been used for treatment of COVID-19 patients 
because of their ability to modulate cellular and humoral immune responses [123,124]. JAKi can 
reduce viral replication, as described for ruxolitinib in HIV inhibition in in vitro and mouse models, 
and for baricitinib in SARS-CoV-2 inhibition of host proteins (numb associated kinases) involved 
in viral entry and replication [125–127]. A total of 12 studies using JAKi for Covid-19 treatment are 
reported (ruxolitinib, n = 3; baricitinib, n = 8; and tofacitinib, n = 1), showing a clinical benefit of 
this drug class in reducing invasive mechanical ventilation needs in severe COVID-19 patients 
presumably more likely in females, while not influencing hospitalization length [128–130]. 
However, these studies have several limitations: recruited patients were mostly males, and JAKi 
therapy was likely confounded by other concomitant interventions, such as the anti-complement C5 













Summary of highlights, strength and limitations of immunosuppressive therapy in COVID-19 patients. 
 
8. Glucocorticoids 
After an initial stage of viral replication, SARS-CoV-2 infection can be followed by a second stage 
characterized by a hyperinflammatory response that dysregulates cytokine secretory patterns [133]. 
This condition drives lung epithelial cells and vascular endothelial cells injury leading to lung 
infiltration of neutrophils and macrophages. Recent studies show that the pro-inflammatory pattern 
has been driven by IL-6 as well as other cytokines/chemokines [134]. Male patients are reported to 
have higher plasma levels of IL-8 and IL-18, while females show T cell activation more 
consistently than males during SARS-CoV-2 infection [100]. Given the hyperinflammatory 
response to SARS-CoV-2 virus, the rationale of glucocorticoid (GC) use in treating COVID-19 is to 
decrease the inflammatory responses in the lungs and control the acute lung injury and acute 
respiratory distress syndrome [77]. GCs are used in clinical practice in patients with severe COVID-
19 disease who require oxygen supplementation with or without an invasive or non-invasive 
mechanical ventilation. A recent systematic review and meta-analysis shows that GCs are 
associated with decreased all-cause mortality in severe COVID-19 patients with no increase in the 











inflammatory hormones, and that sex hormones may also have immune-modulatory functions, a 
link between GCs and sex hormones emerges from several studies (see relevant Summary Box) 
[136]. 
A WHO prospective meta-analysis reported the association between systemic GC use and mortality 
among critically ill patients with COVID-19. In the specific subgroup analysis, they found no 
evidence that the effect of GCs on 28-days mortality varied with age (<=60 vs 60+) or gender [137]. 
With a large number of clinical trials assessing the use of corticosteroids in patients with COVID-
19, two observational studies analyzed gender difference in relation to corticosteroid use. The first 
study by Wu et al., conducted in China in 382 patients, of which 226 on treatment with GCs (150 
males, 76 females), reported that GCs were used significantly more frequently in men (p=0.0135) 
and in younger patients (p=0.0077) [138]. The other observational study by Monedero et al. 
conducted in Spain and Andorra evaluated 882 patients, of which 691 received GCs [139]. Patients 
were stratified into those who received early (before or within the first 48 hours in the ICU) or 
delayed GCs (>48 h after admission to the ICU) and those who did not receive GCs. Females 
receiving early- and delayed GCs were 153/485 and 72/206, respectively (no statistical difference 
between groups was found). No statistical difference in patient age was observed between groups 
(p=0.06). The Authors also compared mortality for early vs non-early GC patients: in the sensitivity 
analysis of the study, use of early GCs was not as effective in women and patients with age <60 
years, while a statistical difference was seen among male patients (hazard ratio: 0.68; CI 0.51-0.90; 
p=0.006) and patients ≥ 60 years (hazard ratio: 0.69; CI 0.54-0.89; p=0.004). 
 
8.1 Clinical trials on glucocorticoids  
Two studies assessing the use of GCs for COVID-19 and reporting stratification of results by sex or 
outcomes for pregnant women in the summary schedule were found in clinicaltrials.gov. Only one 











studies has reported outcomes yet. Moreover, although GCs are mentioned in the intervention 
section, information about neither results by specific treatment and gender nor stratification of pre- 
and post-menopausal women was found in the summary schedule. 
 
 
Summary of highlights, strength and limitations of antiviral corticosteroid therapy in COVID-19 patients. 
  
9. Monoclonal antibodies directed towards the cytokine storm 
Multiple viral pathogens are known to induce a hyperinflammatory state, the so-called "cytokine 
storm". This has been considered as a prognostic factor for more severe clinical course of COVID-
19. Based upon this evidence, the use of mAbs against ILs or IL receptors has been proposed as a 
useful therapeutic strategy to prevent clinical worsening and death. In this regard, drugs able to 
block inflammatory pathway such as TCZ, a humanized IgG1 mAb directed against IL-6R, have 
been commonly used for most severe cases. TCZ binds IL-6 receptors and blocks intracellular 
signal transduction. This action has effects on both the immune system, considering that it inhibits 
the action of inflammatory mediators involving B and T lymphocytes and inflammation, because it 
inhibits the production of acute phase proteins [140]. Several clinical trials investigated the 











open-label studies in COVID-19 patients [141–143]. However, the usefulness of this treatment has 
been questioned by negative results [144,145], and some Authors remained critical [142].  
Sarilumab, a fully IgG1 mAb against IL-6R, was reported not to be effective in a recent publication 
(highlighting the need for adequately powered trials involving biological immunomodulatory 
therapies for severe COVID-19) [146]. During the cytokine storm CD4
+
 T lymphocytes rapidly 
convert into pathogenic Th1 cells with production of GM-CSF also in the lungs. Therefore, 
strategies to reduce GM-CSF levels have been proposed as possible mechanisms for reversing such 
pathologic condition. In this light, drugs acting in synergism with antiviral agents that block GM-
CSF, such as the mAb gimsilumab, have been tested for lung injury or Acute Respiratory Distress 
Syndrome (ARDS) due to COVID-19 in a phase 2 clinical trial (NCT04351243). This trial enrolled 
severe COVID-19 patients who were either male or non-pregnant females 18 or older. Another 
experimental strategy that is being pursued is blocking of IL-1 cascade. However, the anti-IL-1β 
mAb canakinumab, under investigation in phase 3 randomized double-blind trials in hospitalized 
COVID-19 with pneumonia and cytokine release syndrome in patients of both sexes, failed to meet 
primary and secondary endpoints according to a statement from Novartis (NCT04362813-
CANCOVID). On the other hand, intramuscular anakinra was shown to prevent respiratory failure 
in a subclass of COVID-19 patients [147] and an observational retrospective study, part of the 
COVID-19 Biobank study (NCT04318366), comparing anakinra at low or high dose in severe 
COVID-19 patients, evidenced a possible efficacy and safety of the higher dose when given in the 
right timeframe [148].  
 
9.1 Sexual dimorphism of mAb disposition and efficacy 
Fluctuations in hormonal status due to pharmacological intervention (hormone replacement 











drugs, including biological agents [149]. mAbs are metabolized by several mechanisms, one of 
which is the interaction with macrophage FcR or Fcɣ receptor that bind the tail of antibodies, while 
the FcRn protects IgG from intracellular catabolism. Thus, the clinical outcome of mAb therapy 
may be improved by increasing FcR avidity. This could be a future perspective for improving mAb-
based COVID-19 therapy, considering that lung disposition may represent a limitation for these 
treatments. Interestingly, mAb can cross the placental barrier through FcRn-mediated transport 
ending up with passing maternal Ab in the fetal circulation [150,151]. Therefore, mAbs holding the 
Fc portion can cross the placenta during the third trimester since such portion is recognized by 
FcRn. However, limited data are available in regard to mAb in pregnancy and even less so in 
females affected by COVID-19, thus it is very difficult to gain sex-driven information in the 
efficacy and safety profile of mAbs used in this context. 
Interestingly, FcR expression and function are under control of several hormones, including sexual 
hormones. Indeed, it has been reported that estrogens augment IgG clearance by enhancing 
macrophage action mediated through Fc receptor interaction [152], while PG may reduce Fcɣ 
expression leading to higher macrophage-mediated Ab clearance [153]. Furthermore, other 
conditions that are more prevalent in women, such as alteration in thyroid function or increased 
immune response to infectious disease, might modulate mAb disposition and efficacy.  
Although evidence comes mainly from preclinical data, human studies have indicated sex 
differences in mAb pharmacology [154]. In this regard, TCZ displayed a lower clearance rate in 
females compared to males in patients with rheumatoid arthritis [155]. Sex differences clearly exist 
in antibody-mediated effector functions across women and men, tuned by sex-dependent differences 
in response to antibody effector function. However, it should be noted that different reaction to the 
same biological agent might depend not only on sex differences but also on pathogenic conditions. 










agent [156], while it is more effective in males when used as an immunosuppressant in autoimmune 
disease [157].  
 
10. Sex differences in response to COVID-19 vaccines 
Clinical data [158,159] have shown that male and female individuals have different immune 
responses to infections and vaccines: women usually mount a more intense immune response with 
antibody titers even twice as high as those reached in men (see relevant Summary Box). The 
biological mechanisms underpinning the sex bias in vaccine immune response are mainly based on 
sex hormones and genetic/epigenetic mechanisms that can modulate immune responses. However, 
these differences are not considered in dosage and schedule of vaccination. In this context, Engler et 
al. [160] showed that seasonal TIV with half dose of vaccine in women induced protective HI 
antibody titers at levels similar to those induced in men with the full dose. With regard to COVID-
19 vaccines, these have only recently been distributed and become available for widespread use. 
Therefore, data from sex comparison of anti-S antibody titers following vaccination are just starting 
to be available [161]. The phase 2/3 clinical trials of all the new COVID-19 vaccine platforms 
(Pfizer/Biontech, Moderna, Astra Zeneca, Johnson&Johnson and Sputnik vaccines) included men 
and women. Sex-disaggregated data published so far suggest an inverse trend of the response 
between men and women compared to conventional vaccines [162–165]. In fact, higher efficacy has 
been observed in men for the two genomic vaccines (Pfizer, 96.4% in males vs. 93.7% in females; 
and Moderna, 95.4% in males vs. 93.1% in females, respectively) [162,163] as well as for the 
adenoviral vector-based vaccine (Sputnik, 94.2% in males vs. 87.5 % in females, respectively) 
[165]. In the case of AstraZeneca adenoviral-based vaccine, similar humoral and cell mediated 
immune responses were shown in men and women [164]. These results are only preliminary and 
derived from trials on limited number of selected volunteers, thus they await to be confirmed after 











Generally, the greater women immune responsiveness to vaccines is associated with more frequent 
and severe adverse effects of vaccination, duly reported in the AIFA annual report of vaccine post-
marketing surveillance [166]. With regard to currently administered COVID-19 vaccines, 
distribution by gender of the reporting rates entered in the Italian National Surveillance Network, 
published in the AIFA report updated to March 26 [167], shows that the adverse effects were 
significantly more frequent in females (76%) than in males (23%), although the number of 
vaccinated females at the time of data analysis outnumbered that of men. Similarly, the data 
released in February by the US CDC on adverse effects during the first month of the COVID-19 
vaccine showed that, while women received 61% of vaccine doses, 78.7% of side effects reported to 
the agency were from women [168]. Considering the rare and severe adverse effects to vaccines, 
such as allergic reactions, a 2019 study looking at vaccine adverse events reported to the CDC from 
1990 to 2016 found that 80% of the reports of anaphylaxis in vaccinated adults came from women 
[169]. Following the 2009-10 H1N1 (swine flu) pandemic vaccination, four times as many women 
as men reported an allergic reaction to the H1N1 vaccine in the 20-59 age group [170]. In the case 
of COVID-19 vaccines, a severe adverse event seems to be plausibly related to AstraZeneca and 
Janssen vaccine administrations, namely the rare occurrence of thrombosis and thrombocytopenia 
mainly in women under 60 years [171]. EMA and AIFA recommended attention to prodromic 
symptoms of thrombosis in vaccinated individuals, and suggested to limit the use of these two 
vaccines to those over 60. The potential mechanism involved is the production of autoantibodies to 
platelet factor-4 (PF4), which is more common in young female subjects [172]. Various factors may 
contribute to these differences in adverse reaction occurrence, gender-related as well as related to 












The new genomic and virus vector based COVID-19 vaccines await surveillance studies and 
follow-up of mass vaccination to unveil sex disparities in immune response in the same or the 
opposite directions as conventional vaccines. 
 
Summary of highlights, strength and limitations of vaccines for COVID-19 
 
11. Pregnancy and COVID-19 
So far, over 2,000 scientific reports related to COVID-19 and pregnancy have been published. 
However, at present, disease severity in pregnant women is not apparent, and COVID-19 does not 
seem to increase the rate of miscarriage, stillbirth, preterm labor or teratogenicity. Pregnant women 
are not expected to be diagnosed with COVID-19 more than other healthy adults. Approximately 
two-thirds of pregnant women with COVID-19 have no symptoms at all, and most pregnant women 
who do have symptoms only have mild cold, breathlessness or flu-like symptoms, with only a small 
number of them developing severe disease [174]. Therefore, women may be more protected than 
men under physiological conditions including pregnancy or across the menstrual cycle, when 
fluctuation of reproductive steroids confers stronger immune protection. However, a small number 
of pregnant women did develop severe COVID-19. In particular, pregnant women with COVID-19 











women. In fact, physiological changes during pregnancy have an impact on the entire organism 
leading to a potential higher risk of COVID-19 progression. [175,176]. Increased rates of ICU 
admission, need for supplemental oxygen, ventilation and mortality have been observed in pregnant 
women with COVID-19, compared to non-pregnant women [176].  
Two observational studies (NCT04582266: not yet recruiting and NCT04569851: recruiting) 
reported in the “measure outcome section” that they will investigate pregnancy outcomes. Although 
data are limited, pregnant women admitted to hospital with COVID-19 infection are likely to be at 
an increased risk of venous thromboembolic events.  
Pregnancy or breastfeeding are contraindications to DOAC therapy [177], thus heparin would be the 
drug of choice in this case. 
Interestingly, an observational study showed that COVID-19 symptoms severity escalated 
immediately postpartum in some SARS-CoV-2-positive pregnant women, even with mild or no 
symptoms. These observations have been correlated to the hormonal decrease that normally follows 
childbirth [178]. However, further studies are necessary to clarify whether the stress associated with 
the partum and post-partum could affect COVID-19 severity. In fact, stress-associated 
neuroendocrine-immune mechanisms may contribute to an increase in SARS-CoV-2 infection and 
influence the course of COVID-19 disease.  
To date, most SARS-CoV-2-related clinical trials have excluded pregnant women and lactating 
women. This makes it difficult to provide evidence-based recommendations on SARS-CoV-2 
therapies in these vulnerable patients and potentially limits their COVID-19 treatment options. The 
neutralizing monoclonal antibodies tested in the BLAZE-1 study (NCT04427501) included 
pregnant women along with pediatric population, but results have not been published yet. Another 











women upon randomization. Outcomes from these studies are not available yet, but they might 
represent a valid alternative to the use of drugs contraindicated in pregnancy. 
12.  Traditional Chinese Medicine and COVID-19 
Reportedly, since the outbreak start, traditional Chinese medicine (TCM) has been applied to 
control COVID-19 spread along with government measures, public surveillance and utilization of 
conventional Western medicine. The therapeutic role of TCM has been included in guidelines on 
diagnosis and treatment of COVID-19 [179]. Use of traditional medicine to fight COVID-19 may 
be an option in low-income countries as well as in China. 
A systematic review and meta-analysis based on 18 randomized controlled trials involving 2275 
patients evaluated the clinical evidence on TCM for COVID-19 treatment. Compared with the 
conventional Western medicine-treated group, patients in the TCM-treated group showed 
significant improvements in lung computed tomography, clinical cure rate, ranging from mild to 
critical cases, length of hospital stay, total score of clinical symptoms and inflammatory biomarkers, 
with no evidence of severe adverse effects, discomfort or abnormal liver and kidney function [180]. 
Furthermore, a recent review of clinical studies suggested that TCM in combination with 
conventional Western treatment may be superior than conventional Western therapy alone in 
shortening the duration of main symptoms, reducing the aggravation rate and increasing the 
recovery rate [181]. Consistently, the combination of Chinese and Western medicines appears to be 
the mainstream for treatment of COVID-19 in China [182]. A retrospective study based on a real-
world database suggested benefit in terms of lower mortality in patients receiving Qingfei Paidu 
Tang, a formula of TCM [183]. This appears to be one of the very few studies where the association 
was consistently found across sex and age subgroups. Findings from natural product and TCM 
databases may provide useful hints for mechanistic investigations [184] but tend to overestimate 











With regard to potential mechanisms, several TCM preparations activate ERs and flavonoids have 
estrogen-like effect. For instance, Salvia miltiorrhiza (Danshen) significantly upregulates ERα and 
ERβ mRNA and protein expression, increases serum E2 levels and decreases follicle stimulating 
hormone and luteinizing hormone levels, whereas daidzein and genistein produce estrogen-like 
effects [185]. Overall, available data of TCM protection against CoVID-19 do not adequately take 
into account the gender variable. Thus, it would be highly enlightening if an ongoing pilot study of 
a combination of 13 TCM compounds testing the mixture safety for COVID-19 patients [186] 
performed sex-disaggregated analyses.  
Generally speaking, quality and safety standards of TCM formulas appear to be variable, thus 
limiting widespread acceptance outside China [187]. Finally, specific TCM formulas such as 
Qingfei Paidu decoction could significantly modulate the pharmacokinetics of CYP3A substrate-
drugs via inhibition of CYP3A, which on one hand may be exploited to boost immunomodulating 
agents but raises the issue of potential clinically relevant drug interactions when using traditional 
preparations with uncertain potential to interfere with drugs used in COVID-19 treatment [188]. 
13. Discussion and Conclusion 
COVID-19 is currently triggering enormous global demands on health systems and present 
unprecedent challenges to identify effective drugs for prevention and treatment. At present, no 
specific drugs for SARS-CoV2 have been developed yet and all patients have been treated with off-
label or repurposed drugs (Figure 2). In the meanwhile, antibodies against the spike protein of 
SARS-CoV-2 and several vaccines are now becoming available. Unthinkable efforts have been 
made by the scientific community throughout a large number of clinical trials launched worldwide 
to fight and treat COVID-19 using biopharmaceuticals, small molecules and even traditional 
medicine approaches including TCM. However, it is now well established that COVID-19 exhibits 











by the inclusion of men in clinical trials with direct results extrapolation to women, while it is 
imperative to incorporate sex- and gender-related data into trials and analyse treatment outcomes 
disaggregated by sex and gender. Even though it is necessary to consider foetal risk during 
pregnancy, the hormonal interaction due to menstrual cycle or concomitant use of exogenous 
hormones, the complications in recruiting and the higher dropout rate of women, women’s 
recruitment into clinical trials is indispensable.  
Physiological differences in immune response are a Darwinian way to preserve females when 
infected by pathogens because of their importance in survival of the fittest. Moreover, females 
experience three different hormonal phases in their lives (pre-puberty, adulthood, and old age), in 
which the immune status changes because of physiological variations in sex hormones before, 
during and after childbearing age, and because of a natural decline in immune responses due to 
ageing [98]. Therefore, sexual dimorphism in immunity is determined by a combination of several 
factors including sex hormones and age, but also epigenetic changes, environmental factors and 
genetic background [99], and results in greater protection of females against infectious diseases 
compared to males, who are more susceptible to develop tumours and severe symptoms during 
infectious diseases, such as MERS, tuberculosis or hepatitis [98]. 
All the above consideration are in line with differences encountered in COVID-19, where females 
display faster disease resolution and lower risk of thrombosis than males. Indeed, consistent with 
their highly reactive immune system, females experience vaccine-related ADRs to a larger extent 
than male. These facts are summarized in Figure 3. 
Clinical trials should indeed be powered to address sex-specific endpoints in pharmacological 
evaluation. This approach would help to avoid missing opportunities for identifying appropriate 
personalized sex- and gender-specific treatments and to achieve equality. Contrariwise, reinforcing 












It has been too often overlooked by the scientific community, regulatory agencies and 
pharmaceutical companies that the initial phases of clinical trials are particularly and crucially 
important for detecting sex-related differences regarding pharmacokinetics and pharmacodynamics 
and providing data required to proceed to the following phases. In this regard, cost and economics 
should not be reasons for not conducting analyses by sex or of possible interactions of both 
endogenous and exogenous hormones with drugs. This is particular true for both basic and applied 
research. 
In conclusion, the Authors believe that, based on the relevant differences coming from the studies in 
the current literature, a sex- and gender-related approach is crucial and cannot be ignored anymore. 
Indeed, a call on scientists and medical Institutions to acknowledge the critical role of sex- and 
gender-specific investigation to develop a fair approach to prevention and treatment addressing the 
acute and long-term effects of this pandemic focusing on appropriateness and health equity towards 




















Figure 2. Classes of drugs and vaccines used to treat or prevent SARS-CoV-2 infection and 
development of COVID-19. Blue colour highlights prevalence in male vs. female sex. Pink colour 
highlights prevalence in female vs. male sex. Black colour indicates no significant differences 












Figure 3. COVID-19-related effects attributable to sex steroid action/sexual differentiation/gender. 
Differences have been depicted following comparison between male and female individuals 
according to age, and with respect to pregnancy, premenopausal or post-menopausal condition. 
Disease outcomes (e.g. infection and symptoms severity, inflammatory state, risk of thrombosis) are 
shown in green for young and pregnant females, indicating a protective condition. Detrimental 
conditions exacerbating COVID-19 (young and elderly males, post-menopausal females) are shown 
in red. 
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Table 1. RAAS System 
 
Drugs Approval (EMA) Mechanism of action Potential mechanism 
of action on COVID-
19 
Advice (EMA) Sex perspective 
ACEIs First-line 
treatment for 





patients over 55 
years with 
hypertension. 
Inhibition of the 
activity of angiotensin-
converting enzyme, 
component of the 
RAAS system, which 
converts angiotensin 
I to angiotensin II, a 
vasoconstrictor, and 
hydrolyses bradykinin, 
a vasodilatator.  
 
Increasing of ACE2 
expression, 
facilitating SARS-
CoV-2 entry into 
cells. 
Increasing risk of 
contracting 
SARS-CoV-2 is 






19 positive must 
continue to use 
ACE inhibitors 




in relation to 
sex 
ARBs Treatment of 
patients with 
hypertension and 
heart or kidney 
diseases. 
Binding and inhibition 
the AT1 and thereby 
blocking the arteriolar 
contraction and sodium 




Increasing of ACE2 
expression, 
facilitating SARS-
CoV-2 entry into 
cells. 
Increasing risk of 
contracting 
SARS-CoV-2 is 






19 positive must 
continue to use 
ARBs as advised 
by their doctors. 
 
No information 













Table 2 Antiviral therapies overview 





Patients with pneumonia 
under oxygen therapy 
who do not require high-
flow oxygen or 
mechanical ventilation or 
ECMO and with onset of 





Still to be demonstrated 
 
No difference in 
recovery rate ratio 
between male and 


















No information in 
relation to sex  
Higher than umifenovir 
* 
 
No information in 
relation to sex  
Umifenovir No Inhibit several 
stages of the 
viral life cycle 
Under investigation  
 
No information in 
relation to sex  
Safe ** 
 
No information in 
relation to sex 
Favipiravir No Inhibit RNA 
polymerase 
activity 
Under investigation   
 
No information in 
relation to sex  
Favipiravir vs control 
groups: less odds for 
adverse effects in the 




No information in 
relation to sex  
 
ECMO: Extracorporeal Membrane oxygenation 
* T.K. Patel, P.B Patel, M. Barvaliya, M.K. Saurabh, H.L. Bhalla, P.P. Khosla. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic 
review of randomized controlled trials. J Infect Public Health. (2021);14(6):740-748. doi:10.1016/j.jiph.2021.03.015 
**D. Huang, H. Yu, T. Wang, H. Yang, R. Yao, Z. Liang. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic 
review and meta-analysis. J Med Virol. (2021);93(1):481-490. doi:10.1002/jmv.26256 
***S. Hassanipour, M. Arab-Zozani, B. Amani, F. Heidarzad,M.  Fathalipour, R. Martinez-de-Hoyo. The efficacy and safety of Favipiravir in 
treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. (2021);11(1):11022. doi: 10.1038/s41598-021-90551-6.  
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